A Phase 2 interventional study of [18F]-DPA-714 in Triple Negative Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 3 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Institut Cancerologie de l'Ouest · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Triple Negative Breast Neoplasms with a site in France — 35 open to participants now, 66 under way, 13 of them phase 3. Triple Negative Breast Neoplasms · France.
Among the 125 studies in Triple Negative Breast Neoplasms with a site in France, this one is the 113th largest by enrollment of the 119 interventional ones that give a count, is one of 14 that started in 2020, is one of 25 in phase 2, and was the 55th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →35 of the 125 studies in Triple Negative Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:
Center Eugene Marquis · Sites in France
Ages 18+ · Women only
Institut Curie · Sites in France
Ages 18+ · Women only
Pfizer · Sites in France, United States, Spain
Ages 18+
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Canada and 4 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 47 · Phase 3 24
First in 2008; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 182 across the 119 interventional studies, 132 across the 6 observational. Of the 55 that completed or were terminated, 25 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 125 have an industry lead sponsor. The 10 most frequent:
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
Institut Cancerologie de l'Ouest has 3 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies in Triple Negative Breast Neoplasms with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT04595565Phase 3GBG Forschungs GmbHSacituzumab Govitecan in Primary HER2-negative Breast Cancer | 2027-03-30 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT03915678Institut BergoniéAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 125 studies in Triple Negative Breast Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and [18F]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.
The purpose of this study is to evaluate the correlation of inflammation assessed by M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and [18F] DPA-714 PET imaging by using qualitative and image texture analysis in patients with triple negative breast cancer.
Patients receive pre-therapeutic diffusion-weighted breast MRI (Magnetic resonance imaging) and 18FDG (fluorodeoxyglucose) PET/CT (Positron Emission Tomography/Computerized Tomography) scan within 30 days before enrollment.
[18F] DPA-714 PET/CT scan is performed before surgery. About 3 MBq/Kg of [18F] DPA-714 are injected intravenously, two acquisition sequences are performed following injection and 60 minutes after injection in order to evaluate early and late tumor uptake of [18F] DPA-714.
Surgery is scheduled after [18F] DPA-714 PET/CT scan. Tissue samples from breast surgery are used to assess M1 and M2 macrophages expression and to perform tumor molecular subtyping by Immunohistochemical analysis. Tumor Autoradiography with the TSPO (18 kDa Translocator Protein) ligand [18F]DPA-714 will be also assessed on tumor tissue.
A blood sample is performed before [18F] DPA-714 PET/CT scan in order to assess the genotyping of TSPO (18 kDa Translocator Protein) gene.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Triple negative primary breast cancer based on immunohistochemical results as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\[18F\]-DPA-714 PET/CT scan
Drug: [18F]-DPA-714
\[18F\]-DPA-714
Number of Participants With Predominance of M2-Polarized Macrophages
Intratumoral macrophages were quantified by immunohistochemistry on surgical tumor specimens. CD68-positive cells were used to quantify the total macrophage population (M1 and M2 macrophages), whereas CD163-positive cells were used to identify M2-polarized macrophages. The percentage of M2 macrophages was calculated as the proportion of CD163-positive cells among all CD68-positive macrophages. Results are presented as the number of participants whose tumors showed a predominance of M2-polarized macrophages.
Time frame: 2 months
Correlation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT
The correlation between the percentage of CD163-positive M2 macrophages (determined by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was assessed using Spearman's rank correlation coefficient.
Time frame: 2 months
Correlation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT
The correlation between intratumoral CD68-positive macrophage infiltration (assessed by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was evaluated using Spearman's rank correlation coefficient.
Time frame: 2 months
Distribution of [18F]DPA-714 PET/CT Tumor Uptake Patterns According to TSPO Genotype (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder)
Tumor uptake patterns were classified as above, equal to, or below muscular background and are presented descriptively according to TSPO genotype (HAB, MAB, LAB). No formal statistical analysis was performed because of the limited sample size.
Time frame: 2 months
Slope of Tumor Time-Activity Curves During Early [18F]-DPA-714 PET/CT Acquisition
Early tumor uptake was assessed using dynamic PET/CT time-activity curves (TACs). Results are presented as the slope of tracer accumulation derived from tumor TACs. Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background.
Time frame: 1 month
Primary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI
Primary tumor detection was assessed qualitatively using \[18F\]-DPA-714 PET/CT, 18F-FDG PET/CT, and diffusion-weighted breast MRI. Results are presented as the number of participants in whom the primary tumor was identified by each imaging modality.
Time frame: 1 month
[18F]-DPA-714 Toxicity
Number of patients with adverse events and serious adverse event after \[18F\]-DPA-714 administration
Time frame: 1 month
Tumor SUVmean During Late [18F]-DPA-714 PET/CT Acquisition
Late tumor uptake was assessed during the plateau phase of dynamic \[18F\]-DPA-714 PET/CT time-activity curves (TACs). Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background. Results are presented as median SUVmean values and ranges for each uptake pattern.
Time frame: 1 month
| Milestone | [18F]-DPA-714 PET/CT |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
Intratumoral macrophages were quantified by immunohistochemistry on surgical tumor specimens. CD68-positive cells were used to quantify the total macrophage population (M1 and M2 macrophages), whereas CD163-positive cells were used to identify M2-polarized macrophages. The percentage of M2 macrophages was calculated as the proportion of CD163-positive cells among all CD68-positive macrophages. Results are presented as the number of participants whose tumors showed a predominance of M2-polarized macrophages.
| Participants | [18F]-DPA-714 PET/CT |
|---|---|
| Preponderance of M2-polarised macrophages | 11 |
| Non preponderance of M2-polarised macrophages | 2 |
The correlation between the percentage of CD163-positive M2 macrophages (determined by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was assessed using Spearman's rank correlation coefficient.
| Spearman correlation coefficient | [18F]-DPA-714 PET/CT |
|---|---|
| Correlation Between % M2 Using CD163 and SUV Max [18F]DPA-714 PET/CT | -0.45 |
The correlation between intratumoral CD68-positive macrophage infiltration (assessed by immunohistochemistry) and tumor SUVmax on \[18F\]DPA-714 PET/CT was evaluated using Spearman's rank correlation coefficient.
| Spearman correlation coefficient | [18F]-DPA-714 PET/CT |
|---|---|
| Correlation Between CD68-Positive Macrophage Infiltration and Tumor SUVmax on [18F]DPA-714 PET/CT | -0.30 |
Tumor uptake patterns were classified as above, equal to, or below muscular background and are presented descriptively according to TSPO genotype (HAB, MAB, LAB). No formal statistical analysis was performed because of the limited sample size.
| Participants | HAB (High Affinity Binder) | MAB (Mixed Affinity Binder) | LAB (Low Affinity Binder) |
|---|---|---|---|
| Above muscular background | 2 | 2 | 0 |
| Equal to muscular background | 3 | 3 | 1 |
| Below muscular background | 0 | 1 | 1 |
Early tumor uptake was assessed using dynamic PET/CT time-activity curves (TACs). Results are presented as the slope of tracer accumulation derived from tumor TACs. Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background.
| TAC slope | Early [18F]-DPA-714 PET Acquisition |
|---|---|
| Above muscular background | 1.35 |
| Equal to muscular background | 0.62 |
| Below muscular background | 0.22 |
Primary tumor detection was assessed qualitatively using \[18F\]-DPA-714 PET/CT, 18F-FDG PET/CT, and diffusion-weighted breast MRI. Results are presented as the number of participants in whom the primary tumor was identified by each imaging modality.
| Participants | [18F]-DPA-714 PET/CT | 18FDG PET/CT | Diffusion-weighted MRI |
|---|---|---|---|
| Primary Tumor Detection by [18F]-DPA-714 PET/CT, 18F-FDG PET/CT, and Diffusion-Weighted Breast MRI | 13 | 13 | 13 |
Number of patients with adverse events and serious adverse event after \[18F\]-DPA-714 administration
| Participants | [18F]-DPA-714 |
|---|---|
| Serious adverses events (SAEs) — Patients with adverses events AEs | 0 |
| Serious adverses events (SAEs) — Patients who did not experience any AEs | 13 |
| Adverses events (AEs) — Patients with adverses events AEs | 0 |
| Adverses events (AEs) — Patients who did not experience any AEs | 13 |
Late tumor uptake was assessed during the plateau phase of dynamic \[18F\]-DPA-714 PET/CT time-activity curves (TACs). Tumors were classified relative to the contralateral pectoral muscle as above muscular, equal to muscular, or below muscular background. Results are presented as median SUVmean values and ranges for each uptake pattern.
| SUVmean | Late [18F]-DPA-714 PET Acquisition |
|---|---|
| Above muscular background | 4.02 (2.09 to 5.31) |
| Equal to muscular background | 1.66 (0.93 to 3.07) |
| Below muscular background | 0.61 (0.43 to 1.02) |
Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| [18F]-DPA-714 PET/CT | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Age, Categorical(Participants) | [18F]-DPA-714 PET/CT |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 6 |
| Sex: Female, Male(Participants) | [18F]-DPA-714 PET/CT |
|---|---|
| Female | 13 |
| Male | 0 |
| Race and Ethnicity Not Collected(Participants) | [18F]-DPA-714 PET/CT |
|---|
| Region of Enrollment(participants) | [18F]-DPA-714 PET/CT |
|---|---|
| France | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Jul 2021, 13 months.
Results were first posted in Nov 2026, 5 years 3 months after primary completion.
Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's 13 months is below that.
Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triple Negative Breast Neoplasms →
Institut Cancerologie de l'Ouest →